primari
task
microbiologicalmycolog
diagnost
provid
adequ
inform
infect
caus
antimicrobi
suscept
optim
period
time
delay
accur
pathogen
identif
appropri
treatment
initi
undoubtedli
affect
diseas
outcom
despit
signific
advanc
medic
technolog
term
rapid
accur
diagnost
laboratori
test
follow
new
therapeut
major
effect
decreas
morbid
mortal
mani
fatal
diseas
wit
invas
fungal
infect
ifi
still
one
biggest
problem
medicin
increas
number
immunocompromis
patient
tcell
mediat
immun
defici
mucosalcutan
barrier
metabol
dysfunct
neutropenia
age
excess
use
antibiot
cytotox
therapi
transplant
predispos
risk
factor
condit
significantli
influenc
higher
incid
ifi
moreov
incid
preval
nosocomi
ifi
still
high
candida
speci
repres
third
common
blood
isol
hospit
patient
ifi
invas
candidosi
intens
care
unit
icu
candida
bloodstream
infect
prolong
stay
icu
mortal
rang
also
caus
complic
clinic
cours
primari
diseas
increas
treatment
cost
oppos
ifi
superfici
fungal
infect
sfi
keratin
rich
structur
rare
system
seriou
infect
caus
commonli
dermatophyt
yeast
nondermatophyt
mold
repres
one
domin
infect
worldwid
global
preval
rang
lack
rapid
diagnost
method
sfi
consequ
influenc
physician
gener
practic
dermatologist
requir
mycolog
analys
prescript
empir
treatment
system
antifung
addit
infect
affect
patient
qualiti
life
potenti
caus
social
profession
emot
problem
thu
tradit
cultur
base
method
diagnosi
fungal
infect
still
consid
gold
standard
time
consum
low
sensit
therefor
order
overcom
limit
mani
research
focus
develop
new
immunolog
molecular
base
rapid
assay
could
enabl
earli
diagnosi
infect
accur
identif
fungal
pathogen
caus
superfici
invas
infect
brief
review
highlight
advantag
disadvantag
convent
diagnost
method
possibl
noncultur
base
assay
diagnosi
superfici
fungal
infect
present
overview
current
avail
immunochromatograph
assay
well
avail
biomark
detect
immunodiagnost
procedur
prompt
accur
diagnosi
invas
fungal
infect
addit
present
diagnost
effici
current
avail
molecular
panel
research
area
c
elsevi
masson
sa
right
reserv
fungal
infect
skin
nail
hair
could
consid
cosmet
problem
rel
minor
signific
given
fact
deep
infect
dissemin
pathogen
expect
immunodefici
genet
abnorm
mutat
leukemia
prompt
diagnosi
treatment
sfi
could
prevent
complic
unwant
clinic
outcom
far
group
sfi
mucos
oropharyng
vulvovagin
intestin
fungal
infect
also
includ
today
preval
oropharyng
vulvovagin
mucos
candidosi
candidaovergrowth
intestin
significantli
rise
treatment
chronicrecurr
form
big
challeng
physician
also
frequent
chang
local
therapi
system
goal
improv
treatment
probabl
influenc
emerg
resist
candida
speci
azol
new
highli
specif
sensit
rapid
test
disabl
misdiagnosi
unnecessari
proscrib
antifung
accord
recent
initi
appeal
system
antifung
kept
ifi
histor
often
highlight
tradit
convent
method
diagnosi
sfi
ifi
time
consum
low
sensit
propagatingcultiv
caus
agent
method
defici
requir
time
isol
conduct
uniqu
analysi
provid
antigen
ag
detect
molecular
biochem
identif
etiolog
agent
antimicrobi
suscept
test
hand
histopatholog
examin
tissu
sampl
consid
gold
standard
ifi
major
shortcom
lay
complex
invas
biopsi
procedur
review
discuss
current
avail
data
advantag
disadvantag
rapid
assay
fungal
detect
identif
diagnosi
sfi
ifi
rapid
assay
diagnosi
superfici
fungal
infect
sfi
convent
microscop
examin
cheap
easyto
use
fast
method
detect
fungi
patient
sampl
although
stain
procedur
offer
addit
inform
concern
morpholog
microorgan
form
wet
mount
techniqu
provid
rapid
detect
fungal
blastoconidiayeast
pseudohyphalhyph
form
patient
materi
fig
wet
mount
chlorlactophenol
koh
reagent
still
irreplac
techniqu
screen
patient
suspect
sfi
skin
hair
nail
addit
diagnosi
vagin
discharg
wet
mount
microscopi
use
diagnosi
candida
vagin
one
preval
genit
infect
women
nowaday
specif
stain
chemic
fluoresc
dye
acridinorang
calcofluor
wight
blankoflor
improv
visual
detect
fungi
current
effort
establish
imunochromatograph
ic
assay
determin
dermatophyt
candida
ag
repres
signific
progress
diagnosi
sfi
genit
candidosi
respect
fast
easi
perform
easi
interpret
assay
satisfactori
replac
far
report
ic
assay
trichophyton
antibodi
ab
use
colloid
gold
particl
captur
ag
differ
dermatophyt
speci
rubrum
mentagrophyt
violaceum
tonsuran
microsporum
cani
gypseum
epidermophyton
floccosum
compar
diagnost
perform
ic
dermatophyt
detect
skin
nail
sampl
higashi
et
al
report
ic
sensit
specif
specimen
scarifi
skin
sampl
taken
nail
plate
respect
base
result
author
recommend
ic
assay
easi
use
rapid
tool
screen
dermatophyt
infect
definit
diagnosi
cultur
still
recommend
method
studi
conduct
noriki
ishida
inhous
develop
ic
assay
show
good
diagnost
perform
dermatophyt
detect
nail
sampl
similarli
anoth
ic
assay
use
colloid
goldantimannan
igg
conjug
candida
detect
vagin
swab
report
recent
advantag
newli
develop
ic
assay
possibl
use
clinic
laboratori
detect
candida
spp
concentr
cfuml
patient
sampl
min
without
expens
equip
howev
comparison
cultur
ic
candida
assay
vagin
swab
show
high
specif
posit
predict
valu
follow
lower
sensit
neg
predict
valu
c
albican
second
preval
speci
c
glabrata
caus
moreintens
chronic
form
genit
candidosi
concentr
cfuml
patient
sampl
despit
data
refer
literatur
lack
commerci
ic
assay
sfi
research
design
establish
assay
sfi
great
signific
support
convent
method
facilit
diagnosi
dermatophytosi
genit
candidosi
women
last
forti
year
number
molecular
techniqu
develop
identif
dermatophyt
speci
strain
level
includ
fingerprint
method
convent
pcr
employ
select
genet
marker
eg
intern
transcrib
spacer
chitin
synthas
gene
topoisomeras
ii
gene
small
larg
ribosom
rna
subunit
nontranscrib
spacernt
region
restrict
fragment
length
polymorph
rflp
total
mitochondri
dna
mtdna
analys
chang
view
taxonomi
dermatophyt
molecular
diagnosi
provid
specieslevel
identif
dermatophyt
accur
regard
develop
human
soil
anim
recent
studi
show
convent
pcr
region
might
help
tool
better
understand
dermatophyt
identif
taxonomi
ecolog
epidemiolog
find
revolution
diagnosi
sfi
caus
dermatophyt
use
hous
rare
commerci
molecular
tool
enabl
rapid
determin
directli
patient
sampl
within
h
hous
molecular
tool
variou
type
pcr
techniqu
develop
last
decad
assay
evolut
convent
pcr
nest
pcr
pannest
pcr
recommend
gold
standard
higher
sensit
compar
convent
method
follow
multiplex
realtim
pcr
provid
detect
rubrum
interdigital
violaceum
audouinii
later
develop
singletub
dermatophyt
qpcr
tool
base
sequenc
design
allow
determin
speci
three
dermatophyt
genera
trichophyton
microsporum
epidermophyton
directli
patient
sampl
besid
report
multiplex
pcr
detect
rubrum
mentagrophyt
nail
sampl
base
chitin
synthas
region
prove
molecular
tool
excel
diagnost
perform
sensit
specif
commerci
assay
also
design
high
diagnost
perform
duplex
pcr
combin
pandermatophyt
pcr
trichophyton
rubrumspecif
pcr
assay
provid
rapid
detect
identif
trichophyton
rubrum
nail
specimen
shown
specif
sensit
respect
comparison
convent
method
hand
multiplex
pcr
method
dermathophyt
dermatophytescandida
speci
clinic
sampl
also
develop
clinic
evalu
still
progress
recent
publish
result
show
realtim
pcr
specif
pandermatophyt
primer
detect
agent
group
fungi
clinic
sampl
detect
infect
patient
compar
howev
unsatisfactori
sensit
posit
predic
valu
method
suggest
yet
suffici
replac
convent
diagnosi
addit
new
data
tinea
capiti
subsaharan
africa
highlight
import
earli
detect
caus
agent
use
pcrelisa
rapid
determin
antropophyl
speci
violaceum
audouinii
soudanens
rubrum
allow
effect
appropri
therapi
monitor
possibl
sourc
infect
implement
prevent
measur
goal
prevent
spread
caus
agent
infect
mean
develop
standard
well
commerci
molecular
tool
great
import
perspect
rapid
diagnost
sfi
prolong
surviv
highrisk
patient
transplant
immunodefici
immunomodulatori
regimen
malign
longer
stay
icu
etc
ifi
primarili
depend
time
accur
diagnosi
antifung
treatment
rapid
advanc
field
diagnost
method
prompt
diagnosi
ifi
caus
candida
spp
aspergillu
spp
pneumocysti
jirovecii
p
jirovecii
achiev
recent
year
howev
standard
current
avail
immunolog
pcr
fluoresc
situ
hybrid
assay
still
ongo
worldwid
besid
develop
util
highli
specif
sensit
diagnost
test
detect
ifi
caus
fungal
speci
also
requir
convent
method
design
rapid
assay
diagnosi
ifi
summar
tabl
convent
use
diagnosi
ifi
requir
high
level
expert
knowledg
repres
main
disadvantag
procedur
detect
invas
aspergillu
hypha
direct
microscop
examin
sampl
obtain
primarili
steril
region
equat
proven
invas
fungal
diseas
hand
infect
probabl
patient
posit
microscop
find
sputum
broncho
alveolar
lavag
bal
fluid
combin
appropri
clinic
criteria
predispos
factor
also
cryptococ
mening
rapidli
diagnos
encapsul
cryptococcu
neoforman
cri
neoforman
yeast
cell
visibl
cerebrospin
fluid
csf
ad
indian
ink
wet
mount
csf
sediment
improv
cryptococcu
detect
diagnost
efficaci
specif
stain
patient
sampl
giemsa
wright
wrightgiemsa
fontanamasson
grocottmethenamin
silver
gm
fluoresc
dye
acridin
orang
calcofluor
whight
blankofor
improv
visual
fungi
detect
specif
stain
method
commonli
use
detect
p
jiroveci
carinii
lower
respiratori
tract
specimen
identifi
presenc
intracellular
form
histoplasma
capsulatum
bal
bone
marrow
peripher
blood
smear
touch
prepar
lymph
node
tissu
acridin
orang
allow
detect
p
jiroveci
purul
specimen
fluoresc
stain
bind
cellulos
chitin
fungal
cell
wall
becom
use
tool
laboratori
mycolog
also
fungi
detect
method
identif
difficult
imposs
mani
case
import
advantag
immunoassay
possibl
perform
directli
clinic
sampl
obtain
patient
ic
assay
fungal
ag
lowcost
easi
use
applic
patient
bedsid
perform
easi
number
sampl
without
special
equip
even
without
electr
howev
current
commerci
avail
immunochromatograph
assay
enabl
detect
surfac
solubl
yeast
aspergillu
ag
clinic
sampl
detail
characterist
present
tabl
one
signific
achiev
mycolog
develop
evalu
manufactur
immunoassay
diagnosi
ifi
introduct
immunoassay
ag
detect
patient
biolog
fluid
serum
bal
csf
diagnosi
ifi
previous
diagnos
histopatholog
examin
tissu
sampl
biopsi
becom
rapid
non
invas
latex
agglutin
test
cryptococc
gxm
chip
sensit
specif
easi
perform
polysaccharid
capsular
gxm
produc
larg
quantiti
crytococcu
detect
csf
blood
sampl
also
detect
candida
mn
aspergillu
gm
bdglucan
bdg
serum
bal
fluid
significantli
improv
diagnosi
ifi
diagnosi
candidemia
mn
bdg
current
avail
mn
major
compon
candida
cell
wall
account
total
dri
cell
weight
releas
bloodstream
candida
replic
infect
platelia
candida
ag
test
biorad
laboratori
marneslacoquett
franc
enabl
detect
mn
blood
serum
sampl
elisa
format
sever
retrospect
prospect
studi
evalu
util
mn
detect
diagnosi
invas
candidosi
haematolog
icu
patient
overal
sensit
sn
specif
sp
sn
test
seem
vari
infect
candida
speci
highest
case
c
albican
posit
mn
test
occur
sever
day
radiolog
detect
hepatosplen
candidosi
posit
blood
cultur
bc
highrisk
patient
test
perform
two
three
time
per
week
sinc
presenc
mn
ag
blood
shortliv
due
rapid
clearanc
episod
candidemia
concomit
appear
antimn
ab
anoth
agbas
test
detect
presenc
bdg
import
compon
cell
wall
fungi
sera
sampl
approv
food
drug
administr
unit
state
america
test
evalu
mostli
icu
patient
overal
sn
sp
subject
proven
probabl
ifi
howev
bdg
speci
specif
therefor
pan
fungal
assay
result
mani
larg
studi
shown
higher
valu
sn
sp
extrem
low
valu
diagnost
odd
ratio
obtain
bdg
concentr
vari
ifi
due
differ
fungal
speci
white
et
al
prove
bdg
concentr
provenprob
ifi
pgml
significantli
higher
possiblesuspec
case
control
popul
pgml
differ
regard
caus
ifi
bdg
use
diagnosi
invas
aspergillosi
invas
candidosi
p
jirovecii
pneumonia
bdg
concentr
vari
base
caus
agent
addit
posit
bdg
case
p
jirovecii
pneumonia
distinguish
infect
coloniza
tabl
summari
rapid
assay
fungi
identif
invas
fungal
infect
ifi
diagnosi
tion
promot
higher
sensit
bdg
concentr
pg
ml
consid
posit
concentr
threshold
pgml
increas
specif
interpret
could
addit
clinic
radiolog
examin
immunoor
molecular
assay
test
appli
twice
weekli
singl
posit
test
indic
infect
true
posit
case
usual
show
fall
bdg
titter
eventu
becom
neg
patient
respond
antifung
treatment
trend
observ
patient
respond
therapi
fals
posit
bdg
result
may
occur
due
sever
reason
haemodialysi
abdomin
surgeri
treatment
blactam
antibiot
concomit
presenc
lipopolysaccharid
originationg
gramneg
bacteremia
make
applic
rather
difficult
clinic
set
howev
base
excel
neg
predict
valu
test
nearli
lack
bdg
detect
use
exclus
ifi
also
colon
individu
candida
sp
appar
effect
bdg
test
outcom
use
gm
diagnosi
invas
aspergilosi
recent
publish
data
suggest
detect
aspergillu
ag
blood
parallel
pcr
diagnost
provid
high
sensit
specif
influenc
neg
predict
valu
high
risk
patient
enabl
consider
noexist
invas
aspergillosi
patient
need
antifung
therapi
contrari
posit
test
posit
predict
valu
suggest
probabl
occurr
invas
aspergillosi
howev
crossreact
fusarium
spp
aspergillu
gm
elisa
assay
observ
need
taken
consider
patient
contrari
set
signific
progress
diagnosi
infecti
diseas
fungal
infect
includ
made
introduct
molecular
biolog
molecular
detect
identif
well
nucleic
acid
test
nat
great
import
diagnosi
infecti
diseas
especi
presenc
suggest
patient
histori
clinic
manifest
infect
method
use
sensit
specif
tool
detect
identif
numer
microorgan
patient
specimen
applic
nat
enhanc
speed
diagnosi
test
complet
hour
high
sn
sp
howev
disadvantag
includ
high
cost
reagent
instrument
appropri
train
staff
wellequip
laboratori
abl
fulfil
highest
standard
addit
possibl
sampl
reagent
contamin
could
also
lack
assay
peptid
nucleic
acid
fluoresc
situ
hybrid
pnafish
brand
new
rapid
molecular
diagnost
platform
develop
advandx
woburn
massachusett
base
proprietari
pna
probe
technolog
pnafish
use
varieti
current
approv
probe
includ
one
staphylococcu
aureu
coagulaseneg
staphylococci
con
enterococcu
faecali
enterococci
escherichia
coli
klebsiella
pneumonia
pseudomona
aeruginosa
c
albican
c
glabrata
c
parapsilosi
c
krusei
c
tropicali
advandx
pnafish
use
fluorescentlabel
probe
target
speciesspecif
rrna
sequenc
high
sn
sp
fluoresc
situ
hybrid
assay
probe
bind
target
rna
tightli
without
electrostat
repuls
charg
rna
backbon
sinc
rrna
amplifi
viabl
cell
grow
cultur
need
amplif
cell
lyse
usual
use
isol
genet
materi
also
necessari
sinc
pna
probe
hybrid
rrna
insid
bacteria
yeast
enabl
whole
cell
analysi
assay
requir
limit
sampl
prepar
cell
need
lyse
isol
genet
materi
allow
simpl
test
procedur
visual
result
match
gramstain
morpholog
major
characterist
pnafish
routin
monitor
analys
sepsi
safeti
sp
sn
potenti
highthroughput
test
econom
feasibl
pnafish
easi
perform
clinic
laboratori
requir
signific
capit
equip
cost
unlik
microarray
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectroscopi
malditof
pnafish
method
requir
microscop
equip
fluoresc
lamp
dual
band
filter
result
interpret
accuraci
sp
pnafish
significantli
affect
antibiot
antifung
util
allow
target
therapi
reduct
treatment
durat
overal
reduct
healthcar
cost
increas
benefit
patient
recent
methodolog
addit
improv
introduc
new
quickfish
develop
advandx
enabl
fast
minut
identif
bacteria
yeast
posit
blood
sampl
molecular
diagnosi
p
jirovecii
pneumonia
p
jirovecii
opportunist
unicellular
fungal
pathogen
caus
acut
lifethreaten
pneumocysti
pneumonia
immunocompromis
host
hivinfect
patient
especi
know
hiv
posit
compli
respond
antiretrovir
therapi
pneumocysti
prophylaxi
solid
organ
transplant
haematopoiet
stem
cell
transplant
recipi
patient
malign
diseas
nonhivinfect
patient
receiv
immunosuppress
medic
eg
corticosteroid
monoclon
antibodi
cytokin
inhibitor
autoimmun
inflammatori
diseas
subject
congenit
immunodefici
clinic
cours
infect
acut
sever
hivneg
immunocompromis
patient
hivinfect
host
significantli
higher
rate
mortal
vs
case
howev
patient
may
becom
colon
p
jirovecii
without
sign
symptom
acut
diseas
accord
result
conduct
studi
shown
even
hiv
patient
nonhiv
immunosuppress
patient
asymptomat
carrier
p
jirovecii
patient
pneumocysti
pneumonia
rapid
accur
establish
diagnosi
prompt
treatment
initi
critic
determin
favor
clinic
outcom
consid
fact
p
jirovecii
cultur
vitro
microscop
visual
p
jirovecii
cyst
andor
trophozoit
lower
respiratori
sampl
induc
sputum
bal
fluid
still
remain
gold
standard
diagnosi
pneumocysti
pneumonia
howev
method
larg
subject
nonspecif
low
sensit
depend
skill
experi
observ
type
sampl
despit
disadvantag
still
frequent
use
resourcelimit
laboratori
detect
p
jirovecii
clinic
specimen
appli
particular
immunofluoresc
assay
ifa
compar
calcofluor
white
grocottgomori
methenamin
silver
diffquik
stain
method
significantli
sensit
vs
less
specif
vs
recent
two
decad
introduct
molecular
detect
method
clinic
laboratori
practic
led
signific
progress
diagnosi
pneumocysti
pneumonia
nowaday
method
greatli
expand
scope
applic
also
success
use
investig
potenti
outbreak
scenario
determin
epidemiolog
transmiss
pneumocysti
pneumonia
oppos
convent
microscopi
offer
high
degre
object
pcr
one
popular
molecular
diagnost
techniqu
clinic
microbiolog
moment
report
valuabl
tool
detect
p
jirovecii
differ
noninvas
invas
collect
clinic
sampl
respiratori
tract
addit
newli
develop
improv
version
pcr
assay
realtim
pcr
contribut
signific
reduct
turnaround
time
result
avail
h
includ
dna
extract
overal
increas
diagnost
sensit
compar
ifa
moreov
oppos
nest
pcr
onestep
assay
easier
perform
decreas
risk
carryov
contamin
today
variou
sampl
use
pcr
detect
p
jirovecii
pneumonia
pcr
bal
sampl
higher
diagnost
sensit
comparison
noninvas
sampl
sputum
oropharyng
wash
fluid
difficult
obtain
critic
ill
patient
due
increas
risk
respiratori
deterior
also
patient
nonproduct
cough
suspect
p
jirovecii
pneumonia
induc
sputum
easi
obtain
import
emphas
although
highli
sensit
neg
pcr
result
bal
fluid
provid
reliabl
exclus
p
jirovecii
pneumonia
given
fals
neg
result
occur
mutat
posit
mitochondri
larg
subunit
ribosom
rna
mtlsurrna
gene
p
jirovecii
present
hand
studi
shown
pcr
analysi
oropharyng
wash
fluid
specif
bal
sputum
indic
pcr
detect
p
jirovecii
upper
part
respiratori
tract
good
indic
p
jirovecii
pneumonia
order
overcom
insuffici
specif
pcr
bal
fluid
sputum
rel
new
concept
diagnosi
p
jirovecii
pneumonia
develop
method
character
minim
invas
includ
pcr
detect
cellfre
dna
fragment
dna
present
extra
cellular
differ
bodi
fluid
serum
sampl
pioneer
experiment
studi
shown
diagnost
sensit
pcr
detect
p
jirovecii
dna
sera
may
vari
howev
recent
studi
shown
compar
gm
stain
gold
standard
sensit
cellfre
dna
pcr
bal
fluid
pcr
sputum
pcr
specif
much
higher
mention
studi
analyz
togeth
conclud
diagnost
perform
pcr
serum
dna
depend
larg
amount
sampl
use
dna
extract
dna
extract
method
magnet
bead
method
effici
serum
cell
freedna
extract
proteinas
kphenolchloroform
type
primer
use
detect
pneumocysti
pneumocysti
heat
shock
protein
gene
higher
sensit
specif
pneumocysti
detect
pneumocysti
mt
lsu
rrna
gene
invas
pulmonari
aspergillosi
devast
opportunist
infect
caus
mold
belong
genu
aspergillu
infect
mainli
affect
immunocomprom
host
patient
cancer
hematolog
malign
allogen
hematopoiet
stem
cell
solid
organ
transplant
recipi
especi
lung
transplant
recipi
patient
advanc
aid
present
chronic
granulomat
diseas
recent
year
increas
incid
invas
pulmonari
aspergillosi
note
patient
lympho
prolif
syndrom
medic
icu
patient
particularli
treat
corticosteroid
nowaday
despit
advanc
understand
diseas
develop
highli
effect
antifung
voriconazol
posaconazol
global
mortal
morbid
rate
still
high
time
accur
diagnosi
earli
initi
appropri
antifung
treatment
significantli
improv
diseas
prognosi
diagnosi
invas
pulmonari
aspergillosi
tradit
base
isol
fungi
genu
aspergillu
cultur
combin
cme
radiograph
find
howev
sensit
cultur
low
may
take
long
time
result
besid
cultur
incap
differenti
infect
colon
contamin
hand
inexpens
easytoperform
complementari
diagnost
method
improv
posit
predict
valu
confirm
posit
cultur
result
provid
inform
infect
cell
morpholog
state
infect
tissu
biofilm
format
organ
specif
immuno
assay
base
detect
fungal
cell
wall
biomark
bdg
aspergillu
gm
significantli
reduc
turnaround
time
compar
shown
low
sensit
specif
certain
patient
group
molecular
techniqu
repres
novel
approach
diagnosi
invas
aspergillosi
current
pcr
wide
appli
molecular
diagnost
test
enabl
amplif
detect
extrem
low
concentr
pg
aspergillu
dna
variou
clinic
specimen
bal
fluid
serum
plasma
whole
blood
biopsi
materi
also
pcr
assay
quickli
identifi
speci
within
genu
aspergillu
cultur
noncultur
sampl
great
signific
epidemiolog
studi
clinic
practic
given
fact
newli
describ
speci
aspergillu
lentulu
aspergillu
calidoustu
shown
elev
minimum
inhibitori
concentr
mic
sever
antifung
drug
includ
azol
due
lack
standard
potenti
falseposit
result
pcr
exclud
european
organ
research
treatment
cancer
mycos
studi
group
eortcmsg
definit
group
expert
conduct
investig
aspergillu
pcr
compar
gm
bdg
base
obtain
result
conclud
pcr
matur
enough
inclus
eortcmsg
definit
studi
shown
perform
molecular
test
vari
depend
specimen
type
patient
popul
pcr
analysi
blood
fraction
desir
test
modal
given
requir
minim
invas
sampl
procedur
also
import
emphas
method
less
expos
accident
contamin
comparison
pcr
bal
sampl
offer
higher
diagnost
sensit
screen
moreov
note
diagnosi
invas
aspergillosi
exclud
consist
neg
result
obtain
test
multipl
blood
sampl
conduct
metaanalys
shown
aspergillu
pcr
blood
sampl
achiev
sn
rang
sp
differ
fraction
blood
compar
metaanalysi
show
pcr
assay
whole
blood
sn
vs
less
sp
vs
sera
howev
differ
statist
signific
hand
anoth
studi
includ
hematolog
patient
risk
invas
aspergillosi
report
highest
diagnost
sn
aspergillu
pcr
test
plasma
comparison
pcr
test
serum
whole
blood
disagr
result
two
mention
studi
due
differ
sampl
process
prolong
specimen
storag
method
wholeblood
specimen
use
second
studi
highrisk
patient
least
two
posit
wholeblood
pcr
specimen
per
patient
may
dramat
increas
sp
posit
predict
valu
indic
invas
aspergillosi
howev
approach
significantli
decreas
sn
indic
diagnost
strategi
valuabl
confirmatori
tool
screen
tool
anoth
factor
may
also
affect
sn
pcr
test
current
immunolog
statu
patient
studi
examin
diagnost
perform
pcr
analysi
sera
obtain
neutropen
nonneutropen
patient
shown
test
modal
higher
sn
neutropen
patient
nonneutropen
patient
without
statist
signific
likewis
studi
note
initi
level
aspergillu
dna
highli
predict
mortal
rate
copiesmllow
probabl
copiesmlhigh
probabl
great
signific
identif
patient
may
benefit
intens
care
final
base
fact
conclud
pcr
analysi
serum
plasma
seem
diagnost
modal
accept
sn
sp
also
sampl
type
oppos
whole
blood
requir
preanalyt
cell
lysi
step
allow
biomark
diagnost
test
gm
run
bal
fluid
repres
anoth
commonli
use
sampl
diagnosi
invas
aspergillosi
compar
blood
sampl
sp
aspergillu
pcr
bal
test
significantli
higher
base
result
conduct
metaanalysi
pool
sp
pcr
bal
fluid
specimen
even
proven
probabl
invas
aspergillosi
sn
howev
one
major
limit
pcr
test
respiratori
sampl
inabl
differenti
airway
colon
invas
diseas
also
risk
sampl
contamin
patient
bedsid
laboratori
airborn
spore
high
may
lead
occurr
fals
posit
result
furthermor
estim
even
bal
sampl
healthi
subject
would
fals
posit
molecular
test
significantli
higher
diagnost
modal
eg
detect
gm
quantit
pcr
qpcr
detect
high
fungal
burden
may
indic
invas
aspergillosi
diagnost
modal
still
mani
limit
recent
year
resist
azol
fumigatu
emerg
global
health
problem
base
publish
result
conduct
studi
resist
occur
result
mutat
gene
promot
region
mutat
first
found
netherland
sinc
report
multipl
european
countri
middl
east
asia
africa
australia
unit
state
azoleresist
invas
aspergillosi
difficult
diagnos
use
tradit
culturebas
method
given
aspergillu
cultur
neg
major
patient
hand
immunoassay
provid
detect
fungal
cell
wall
biomark
unabl
identifi
patient
azoleresist
diseas
consequ
two
commerci
multiplex
realtim
pcr
assay
mycogeni
ademtech
pessac
franc
aspergeniu
pathonost
maastricht
netherland
develop
enabl
detect
fumigatu
dna
preval
mutat
respons
azol
resist
clinic
sampl
assay
evalu
use
bal
fluid
serum
sampl
aspergeniu
multiplex
realtim
pcr
test
includ
two
pcr
speci
pcr
resist
pcr
respiratori
sampl
speci
pcr
gener
thesn
sp
respect
patient
hematolog
disord
resist
pcr
abl
detect
resistanceassoci
mutat
cultureneg
patient
invas
aspergillosi
serum
sampl
speci
assay
show
sn
sp
respect
patient
fungal
diseas
statu
previous
defin
use
revis
eortc
criteria
hand
mycogeni
show
thesn
sp
detect
aspergillu
dna
respiratori
sampl
serum
sampl
sn
sp
respect
import
emphas
isol
harbor
mutat
accur
detect
recent
multiplex
pcr
realtim
mpcr
molecular
test
develop
detect
identif
variou
close
relat
pathogen
caus
respiratori
gastrointestin
sexual
transmit
infect
well
mening
sepsi
similar
clinic
symptom
sign
possibl
simultan
presenc
sever
differ
agent
differenti
diagnosi
infect
includ
larg
number
potenti
agent
clinic
indistinguish
use
molecular
panel
allow
time
detect
discrimin
infect
pathogen
import
optim
medic
prevent
secondari
spread
infect
unnecessari
antibiot
use
viral
infect
may
help
decis
regard
hospit
infect
control
measur
also
panel
includ
intern
control
monitor
everi
procedur
step
medic
mycolog
use
multiplex
pcr
pathogen
detect
impli
panel
detect
yeast
blood
patient
sepsi
panel
cri
neoforman
detect
csf
patient
meningitisenceph
characterist
molecular
panel
shown
tabl
recent
year
differ
rapid
molecular
method
develop
speed
identif
microorgan
grow
bloodcultur
bc
bottl
first
place
malditof
ms
sepsityp
kit
tm
use
directli
analyz
posit
bc
real
time
provid
definit
speci
identif
within
minut
identif
rate
malditof
advantag
rapid
turnaround
time
abil
identifi
larg
number
microorgan
directli
disadvantag
includ
high
startup
cost
associ
purchas
massspectrometri
equip
train
personnel
altern
malditof
film
array
blood
cultur
identif
bcid
panel
bio
fire
usa
multiplex
pcr
base
diagnost
test
use
posit
bc
bcid
detect
bacteria
five
candida
spp
three
antimicrobi
resist
determin
mec
van
ab
blakpc
h
time
bc
posit
method
sever
advantag
larg
number
target
evalu
singl
test
step
assay
nucleic
acid
extract
interpret
amplif
data
perform
close
system
use
singl
pouch
minim
process
clinic
sampl
requir
laboratori
procedur
technolog
complex
perform
person
train
molecular
techniqu
method
nano
particl
probe
technolog
nucleic
acid
extract
pcr
amplif
nano
sphere
verigen
use
identif
platform
consist
two
assay
panel
bcgp
assay
bcgn
assay
also
detect
drug
resist
marker
mec
van
ab
kpc
ndm
ctxm
vim
imp
oxa
gene
magnet
reson
mr
assay
rapid
diagnosi
candidemia
whole
blood
one
test
new
era
molecular
diagnost
provid
fast
speci
specif
c
albican
c
tropicali
c
glabrata
c
krusei
c
parapsilosi
detect
directli
clinic
sampl
regard
fact
mr
sensit
specif
requir
cultiv
well
sampl
purif
prepar
highlight
test
repres
exampl
pointofcar
diagnost
test
ensur
prompt
accur
result
ae
hour
possibl
treatment
modif
case
candidemia
novel
technolog
neg
predict
valu
popul
patient
candida
invas
infect
diseas
estim
preval
decreas
number
patient
empir
therapi
resist
strain
occurr
regard
candidemia
caus
c
glabrata
far
consid
fluconazol
flc
resist
common
c
glabrata
echinocandin
often
use
firstlin
therapi
one
major
advantag
mr
possibl
rapid
detect
c
glabrata
blood
patient
higher
sensit
cultur
se
determin
low
level
detect
cfuml
import
sinc
earli
initi
appropri
treatment
improv
prognosi
significantli
decreas
mortal
howev
improv
diagnost
perform
mr
requir
given
nearli
patient
indetermin
dx
result
n
also
price
method
high
enabl
daytoday
monitor
contrarili
bc
addit
speci
candida
detect
assay
howev
resist
echinocandin
therapi
associ
gene
alter
c
glabrata
notic
recent
year
find
influenc
establish
novel
allelespecif
molecular
beacon
dna
melt
analysi
follow
asymmetr
pcr
highli
accur
diagnost
assay
rapid
identif
fk
mutat
associ
echinocandin
resist
candida
speci
platform
diagnost
method
rapid
detect
infect
caus
c
glabrata
resist
strain
echinocandin
time
provid
choic
effici
treatment
current
effort
develop
mass
spectrometryy
ms
procedur
fungal
disaccharid
ds
detect
patient
sera
rapid
diagnosi
ifi
appla
malditof
ms
fungal
molecul
detect
shown
good
diagnost
efficaci
earli
diagnosi
ic
ia
import
invas
mucor
infect
imi
first
research
field
point
fact
sensit
msd
applic
higher
cutoff
higher
mn
bdg
detect
addit
neither
neutropenia
bacteriemia
shown
influenc
detect
fungal
disaccharid
dd
patient
ic
also
method
provid
earlier
posit
result
test
first
serum
sampl
case
ia
moreov
result
evalu
method
suggest
possibl
panfung
analys
diagnosi
imi
current
avail
commerci
serolog
test
effici
diagnosi
howev
highlight
biolog
test
requir
evalu
valid
multicent
studi
delay
diagnosi
ifi
appropri
therapi
applic
clearli
affect
infecti
diseas
outcom
neg
fashion
hand
nonestablish
accur
identif
fungal
pathogen
caus
sfi
influenc
failur
implement
appropri
antiepidem
prevent
measur
era
larg
number
commerci
rapid
test
clinician
must
decid
introduc
routin
work
base
individu
experi
consider
diseas
incid
popul
costeffect
final
adequ
assess
select
patient
would
benefit
rapid
treatment
studi
support
serbian
ministri
educ
scienc
grant
grant
iii
author
declar
compet
interest
